Edition:
United States

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

110.20EUR
18 Aug 2017
Change (% chg)

€0.15 (+0.14%)
Prev Close
€110.05
Open
€109.80
Day's High
€110.55
Day's Low
€108.30
Volume
92,651
Avg. Vol
174,239
52-wk High
€129.85
52-wk Low
€57.36

Latest Key Developments (Source: Significant Developments)

Ipsen delivers H1 sales growth of 18.8%, upgrades its FY 2017 guidance
Thursday, 27 Jul 2017 01:01am EDT 

July 27 (Reuters) - IPSEN SA : :IPSEN DELIVERS STRONG SALES GROWTH OF 18.8% IN THE FIRST HALF OF 2017 AND UPGRADES ITS GUIDANCE FOR FULL YEAR 2017.H1 GROUP SALES REACHED €919.5 MILLION, UP 18.8% YEAR-ON-YEAR.FOLLOWING STRONG PERFORMANCE IN FIRST HALF OF 2017, GROUP UPDATES ITS FINANCIAL TARGETS FOR FULL YEAR 2017.H1 CORE OPERATING INCOME EUR 240.5 MILLION VERSUS EUR 191.3 MILLION YEAR AGO.FULL YEAR 2017 GUIDANCE OF SPECIALTY CARE SALES GROWTH GREATER THAN 24.0PCT.FULL YEAR 2017 GUIDANCE SLIGHT GROWTH OF CONSUMER HEALTHCARE SALES, AND CORE OPERATING INCOME MARGIN GREATER THAN 25.0% OF SALES.  Full Article

Ipsen receives positive CHMP opinion for approval of Xermelo‍​
Friday, 21 Jul 2017 02:27am EDT 

July 21 (Reuters) - IPSEN SA ::RECEIVES POSITIVE CHMP OPINION FOR APPROVAL OF XERMELO‍​.POSITIVE OPINION BASED ON RESULTS OF TWO RANDOMIZED PHASE 3 TRIALS, TELESTAR AND TELECAST.APPROVAL FOR TREATMENT OF CARCINOID SYNDROME DIARRHEA IN PATIENTS INADEQUATELY CONTROLLED BY SOMATOSTATIN ANALOGUE THERAPY‍​.  Full Article

Exelixis, Bristol-Myers Squibb initiate phase 3 trial
Monday, 10 Jul 2017 08:00am EDT 

July 10 (Reuters) - Bristol-myers Squibb Co ::Exelixis and Bristol-Myers Squibb initiate phase 3 trial of opdivo in combination with cabometyx or opdivo and yervoy in combination with cabometyx, versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.Bristol-Myers Squibb Co - ‍exelixis, Bristol-Myers Squibb and Ipsen to co-fund trial​.Bristol-Myers Squibb Co - ‍checkmate 9ER is an open-label, randomized, multi-national phase 3 trial that aims to enroll approximately 1,014 patients​.  Full Article

Ipsen announces Dysport co-promotion agreement with Saol
Friday, 30 Jun 2017 08:00am EDT 

June 30 (Reuters) - Ipsen Sa :Ipsen announces Dysport co-promotion agreement with Saol Therapeutics to expand commercial reach in the united states.Entered into an exclusive, three-year agreement with Saol Therapeutics to promote dysport in United States.Additional details of agreement are not disclosed.  Full Article

Ipsen and Exelixis announce IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib
Monday, 19 Jun 2017 01:26pm EDT 

June 19 (Reuters) - IPSEN SA ::IPSEN SA - IPSEN AND ITS PARTNER EXELIXIS ANNOUNCE INDEPENDENT RADIOLOGY COMMITTEE REVIEW CONFIRMS RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA.E.U. REGULATORY SUBMISSION REMAINS ON TRACK FOR Q3 2017.IRC CONFIRMS CABOZANTINIB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL COMPARED TO SUNITINIB.  Full Article

Ipsen announces FDA approval of Dysport(Abobotulinumtoxina) for treatment of lower limb spasticity in adults
Friday, 16 Jun 2017 12:00pm EDT 

June 16 (Reuters) - IPSEN SA ::IPSEN ANNOUNCES FDA APPROVAL OF DYSPORT (ABOBOTULINUMTOXINA) FOR THE TREATMENT OF LOWER LIMB SPASTICITY IN ADULTS.  Full Article

Ipsen sees 2020 sales to exceed 2.5 billion euros
Thursday, 11 May 2017 01:00am EDT 

May 11 (Reuters) - IPSEN SA : :IPSEN PRESENTS ITS NEW STRATEGY AND IMPROVED 2020 FINANCIAL TARGETS.SEES 2020 SALES TO EXCEED EUR 2.5 BILLION DRIVEN BY SPECIALTY CARE SALES GROWTH ABOVE 14% PER YEAR WITH A GROUP CORE OPERATING INCOME MARGIN GREATER THAN 30% OF SALES.  Full Article

Merrimack reports Q1 loss per share $0.23
Wednesday, 10 May 2017 06:45am EDT 

May 10 (Reuters) - Merrimack Pharmaceuticals Inc : :Merrimack reports first quarter 2017 financial results.Q1 loss per share $0.23.Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Merrimack Pharmaceuticals Inc - declares special cash dividend to stockholders of $140 million.Merrimack Pharmaceuticals Inc - research and development expenses were $21.6 million for three months ended march 31, 2017, compared to $28.0 million.Merrimack Pharmaceuticals Inc - on April 3, 2017, Merrimack received a $575.0 million upfront cash payment from IPSEN.Merrimack Pharmaceuticals - if certain milestones are met pursuant to deal with shire,co expects to receive up to $33.0 million in net milestone payments.Merrimack Pharmaceuticals- used proceeds to redeem $175 million in outstanding senior notes due in 2022, plus about $20 million of costs associated with redemption.Merrimack - currently forecasted spending rates together with net milestone payments from Shire, will be sufficient to fund its operations into H2 of 2019.Merrimack Pharmaceuticals Inc - has also invested $125.0 million in further development of its streamlined oncology pipeline.  Full Article

Ipsen Q1 sales up 19.1 pct at 438.0 million euros
Thursday, 27 Apr 2017 01:00am EDT 

April 27 (Reuters) - Ipsen Sa : :Q1 sales 438.0 million euros ($477.68 million) versus 362.0 million euros year ago.Confirms its objectives for 2017.  Full Article

Merrimack stockholders approve Onivyde, generic Doxil sale to Ipsen
Thursday, 30 Mar 2017 12:00pm EDT 

Merrimack Pharmaceuticals Inc : Merrimack stockholders approve sale of Onivyde and generic version of Doxil to Ipsen for up to $1.025 billion .Expects transaction to be completed in coming days.  Full Article

Pharma group Ipsen raises margin target after strong H1

July 27 French pharmaceutical group Ipsen raised its annual margin target on Thursday on the back of a strong first half, boosted by its core speciality care business which includes oncology and endocrinology products.